Abstract
Pharmacologic support of the failing neonatal heart to maintain cardiac output, which is vital for sufficient end organ perfusion, is a challenging task for the pediatric intensivist, especially since strategies which have been proven to be effective in adults cannot necessarily be extrapolated to neonates. The unique biochemical properties and structure of the neonatal heart, including the increased non-contractile tissue mass, a lower responsiveness to beta adrenergic agents and the heart rate dependent cardiac output with a limited ability toincrease stroke volume, favor some of the new inotropes of the Ca+ sensitizer family. Focusing on the after loadreduction, inodilators as phosphodiesterase inhibitors and human brain natriuretic peptide offer treatment optionsfor the neonatal myocardium. Additionally, thyroxine and steroids have been investigated in neonates with lowcardiac output after surgery for congenital heart disease. Gene therapy, in particular cardiac-selective gene transfer,might offe r perspectives for future support for the neonatal heart. This text reviews some of the most recentpharmacologic strategies targeting the failing myocardium in the critically ill newborn and infant
Mini-Reviews in Medicinal Chemistry
Title: New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant
Volume: 6 Issue: 7
Author(s): Alex Veldman, Stefan Rupp and Dietmar Schranz
Affiliation:
Abstract: Pharmacologic support of the failing neonatal heart to maintain cardiac output, which is vital for sufficient end organ perfusion, is a challenging task for the pediatric intensivist, especially since strategies which have been proven to be effective in adults cannot necessarily be extrapolated to neonates. The unique biochemical properties and structure of the neonatal heart, including the increased non-contractile tissue mass, a lower responsiveness to beta adrenergic agents and the heart rate dependent cardiac output with a limited ability toincrease stroke volume, favor some of the new inotropes of the Ca+ sensitizer family. Focusing on the after loadreduction, inodilators as phosphodiesterase inhibitors and human brain natriuretic peptide offer treatment optionsfor the neonatal myocardium. Additionally, thyroxine and steroids have been investigated in neonates with lowcardiac output after surgery for congenital heart disease. Gene therapy, in particular cardiac-selective gene transfer,might offe r perspectives for future support for the neonatal heart. This text reviews some of the most recentpharmacologic strategies targeting the failing myocardium in the critically ill newborn and infant
Export Options
About this article
Cite this article as:
Veldman Alex, Rupp Stefan and Schranz Dietmar, New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant, Mini-Reviews in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/138955706777698598
DOI https://dx.doi.org/10.2174/138955706777698598 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Iron-Induced Fibrin in Cardiovascular Disease
Current Neurovascular Research Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease
Current Vascular Pharmacology Early Vascular Aging: A New Target for Hypertension Treatment
Current Pharmaceutical Design Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology
Inflammation & Allergy - Drug Targets (Discontinued) Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Current Medicinal Chemistry Gauging Reactive Metabolites in Drug-Induced Toxicity
Current Medicinal Chemistry FXR, A Therapeutic Target for Bile Acid and Lipid Disorders
Mini-Reviews in Medicinal Chemistry Advanced Glycation End Products and Insulin Resistance
Current Pharmaceutical Design Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability
Current Drug Metabolism Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Recommendations for the Treatment of Hypertension in Elderly People
Cardiovascular & Hematological Agents in Medicinal Chemistry Withdrawal Notice: Design and Analysis of Optimization and Tuning in Data Warehouses Using Bitmap Indexes
Recent Advances in Computer Science and Communications Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design Editorial [Hot topic: New Developments in the Treatment and Prevention of Vascular Disease - Part 1 (Executive Editors: N. Katsiki, V.G. Athyros and D.P. Mikhailidis)]
Current Pharmaceutical Design Phenothiazines as Anti-Multi-Drug Resistant Tubercular Agents
Infectious Disorders - Drug Targets Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry